Provention Bio, Inc. (2VB.F)

8.20 +0.54 (+7.08%) At close: 09:15AM CET

Provention Bio, Inc.

55 Broad Street
2nd Floor Red Bank
Red Bank, NJ 07701
United States
908 336 0360
https://www.proventionbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 82

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Ashleigh W. Palmer B.Sc., M.B.A.	Co-Founder, Pres, CEO & Director	900.3k	N/A	1963
Mr. Thierry Chauche	Chief Financial Officer	411.37k	N/A	1976
Dr. Eleanor L. Ramos M.D.	Chief Medical Officer	611.72k	N/A	1956
Dr. Francisco Leon M.D., Ph.D.	Co-Founder & Chief Scientific Officer	N/A	N/A	1972
Ms. Christina Yi	Chief Operations Officer	N/A	N/A	1976
Mr. Robert A. Doody Jr.	VP of Investor Relations	N/A	N/A	N/A
Ms. Heidy Abreu King-Jones J.D., L.L.M.	Chief Legal Officer	N/A	N/A	1983
Kaelan Hollon	VP of Corp. Communications	N/A	N/A	N/A
Mr. Jason Levine	VP Marketing	N/A	N/A	N/A
Sarah O'Brien	Chief People Officer	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Corporate Governance

Provention Bio, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.